Scotiabank analyst Greg Harrison lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $71 from $74 and keeps an Outperform rating on the shares. The firm believes Agios is on track to unlock Pyrukynd’s “blockbuster potential,” the analyst tells investors. However, the firm is lowering its price target on the stock to reflect Q1 reporting.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGIO:
- Agios Pharmaceuticals Reports Q1 2025 Progress and Outlook
- Agios Pharmaceuticals’ Earnings Call: Optimism Amid Challenges
- Agios Pharma’s Strategic Advances and Mitapivat’s Market Potential Drive Buy Rating
- Agios Pharma’s Promising Pipeline and Strategic Readiness Bolster Buy Rating
- Agios Pharmaceuticals reports Q1 EPS ($1.55), consensus ($1.76)